Form 4 for OVID Ovid Therapeutics Inc.
Accepted 2026-07-08 16:31:44 ET · period of report 2026-07-06 · accession 0001779359-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-08 16:31 | 2026-07-06 | OVID | Carter Charles Ross | CFO | A - Grant | $0.00 | +50.0K | 94.4K | +113% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-06 | A | A | 50,000 | $0.00 | 94,375 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. The RSUs will vest in two equal annual installments commencing on July 6, 2027, subject to the Reporting Person's continuous service through each such vesting date. (F2) Each RSU represents a contingent right to receive one share of Common Stock. |